Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Bmy save search
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published: 2023-10-31 (Crawled : 06:00) - biospace.com/
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: 0.83%
H: 0.0%
C: 0.0%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.25%
H: 0.54%
C: 0.29%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.46%
H: 0.0%
C: 0.0%
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 1.39%
H: 0.32%
C: -0.93%
KPTI | $1.085 -3.98% -4.15% 1.6M
|
Health Technology
|
| O: 2.92%
H: 6.08%
C: -3.35%
collaboration trial
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
XYF | News | $3.882 -0.46% 0.0% 340
|
Finance
|
| O: -3.19%
H: 4.87%
C: 4.87%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -4.68%
H: 2.46%
C: -1.83%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 0.16%
H: 0.47%
C: 0.2%
financial results
Global HIV Diagnostics Market Predicted to Reach $1.5 Billion by 2030, with a CAGR of 5.5%
Published: 2023-10-25 (Crawled : 18:00) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.18%
H: 1.34%
C: 1.05%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.31%
H: 0.89%
C: 0.62%
reach global hiv diagnostics market
Samsung Biologics reports third quarter 2023 financial results
Published: 2023-10-25 (Crawled : 07:00) - prnewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.18%
H: 1.34%
C: 1.05%
financial results
Rising R&D Investment and Government Support Fuel Expansion of Global Duchenne Muscular Dystrophy Drugs Market
Published: 2023-10-24 (Crawled : 23:00) - prnewswire.com
PFE | News 4 | $26.32 0.23% 0.0% 24M
|
Health Technology
|
| O: 0.1%
H: 1.77%
C: 0.89%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 2.75%
H: 0.46%
C: -1.76%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.18%
H: 1.34%
C: 1.05%
PTCT | News S | $25.38 -2.27% -2.32% 750K
|
Health Technology
|
| O: -1.34%
H: 2.23%
C: 1.62%
LXRX | $1.62 -5.26% -5.56% 3.5M
|
Health Technology
|
| O: -1.68%
H: 0.85%
C: -2.99%
expansion global duchenne market
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ICPT | $19.0 -0.05% 4M
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
EQ | $1.77 7.27% 6.78% 88K
|
Health Technology
|
| O: 1.16%
H: 3.28%
C: -2.68%
CSTL | $20.02 2.09% 2.05% 200K
|
Health Technology
|
| O: 0.0%
H: 1.87%
C: 0.0%
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.572 12.48% 270
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Published: 2023-10-19 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.37%
H: 0.56%
C: -0.28%
nivolumab renal cell trial
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial benefits
Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
Published: 2023-10-17 (Crawled : 00:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.03%
H: 0.87%
C: 0.38%
lung opdivo cancer cell trial
FDA Roundup: October 17, 2023
Published: 2023-10-17 (Crawled : 21:00) - fda.gov
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.05%
H: 0.33%
C: -0.96%
fda
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens
Published: 2023-10-12 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.04%
H: 0.07%
C: -0.65%
benefits
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
Published: 2023-10-11 (Crawled : 09:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.16%
H: 0.73%
C: 0.3%
disease sclerosis
Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
Published: 2023-10-06 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.3%
H: 1.12%
C: 0.73%
trials
Global HIV Drugs Market Research Report 2023-2031: Long-Acting Injectable HIV Therapies Redefining the Treatment Landscape
Published: 2023-10-02 (Crawled : 17:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 0.19%
H: 0.03%
C: -0.5%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.05%
H: 0.09%
C: -0.28%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
report treatment research global hiv market
Healthcare at Your Fingertips: Global Mobile Medical Apps Market Skyrockets
Published: 2023-09-29 (Crawled : 16:00) - prnewswire.com
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: 1.18%
H: 0.06%
C: -1.62%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: 0.07%
H: 0.48%
C: -0.24%
BSX | $68.99 1.43% 0.19% 9.1M
|
Health Technology
|
| O: 0.17%
H: 0.0%
C: -1.23%
ABT | News | $107.59 0.49% -0.09% 3.8M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: 0.0%
CSCO | News | $48.31 0.35% 0.35% 16M
|
Technology Services
|
| O: 0.52%
H: 0.07%
C: -0.74%
BEAT | $2.04 2.0% 1.96% 28K
|
Health Technology
|
| O: 7.84%
H: 0.9%
C: -2.27%
MDRX | $7.68 -5.66% 240K
|
Technology Services
|
| O: 0.07%
H: 0.0%
C: -1.87%
global medical mobile market
Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb
Published: 2023-09-26 (Crawled : 14:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.49%
H: 0.65%
C: -0.56%
therapeutics milestone
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.49%
H: 0.65%
C: -0.56%
report results
Regenerative Medicine Market Size to Hit USD 44.63 Billion by 2024, with at a 20.16% CAGR Over the Forecast Period | Brandessence Market Research
Published: 2023-09-26 (Crawled : 08:00) - prnewswire.com
NVSEF | News | $95.11 6.88% 490
|
Health Technology
|
| O: -3.05%
H: 1.75%
C: 0.5%
SYK | $334.91 2.21% -4.72% 1.4M
|
Health Technology
|
| O: -0.92%
H: 0.24%
C: -3.93%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.07%
H: 0.46%
C: -0.31%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.49%
H: 0.65%
C: -0.56%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 1.16%
H: 0.13%
C: -0.32%
VCEL | $46.38 2.2% 2.16% 360K
|
Health Technology
|
| O: 0.38%
H: 1.7%
C: -1.85%
BIIB | $193.18 -0.48% -0.48% 1.4M
|
Health Technology
|
| O: -0.02%
H: 1.37%
C: 1.21%
research market
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.